Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Satraplatin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
Satraplatin: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
AUP1602-C Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
AUP1602-C: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CH-5183284 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
CH-5183284: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
E-2730 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
E-2730: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
HMR-59 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
HMR-59: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
AS-1411 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
AS-1411: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CUE-101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
CUE-101: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Oprozomib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 August 2026
Oprozomib: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
IGFBP1 Biologics Sequence Review Report 2026: Insulin-like growth factor-binding protein 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IGFBP1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IFITM5 Biologics Sequence Review Report 2026: Interferon-induced transmembrane protein 5 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFITM5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IFITM1 Biologics Sequence Review Report 2026: Interferon-induced transmembrane protein 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IFITM1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
IGFALS Biologics Sequence Review Report 2026: Insulin-like growth factor-binding protein complex acid labile subunit Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of IGFALS protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.